SOURCE: Xeno Transplants Corporation

January 31, 2008 09:00 ET

Xeno Transplants' Chief Scientific Advisor's Research Published in the New England Journal of Medicine

VANCOUVER, BC--(Marketwire - January 31, 2008) - Xeno Transplants Corporation (OTCBB: XENO), a Nevada Corporation, ("Xeno") is very pleased to call attention to an article published in the New England Journal of Medicine (Kawai et al., N.Engl.J.Med. 358:353-361) on January 24, 2008, which we believe has important implications for the potential success of the Company's strategy for xenotransplantation. The article, co-authored by Dr. David H. Sachs, the Company's chief Scientific Advisor and a member of Xeno's Board of Directors, demonstrates that tolerance to mismatched kidney transplants can be achieved in humans, thereby reducing the risk of rejection of the organ. This is potentially a major breakthrough in the field of transplantation as tolerance facilitates the acceptance of the donor organ by the recipient and provides a means for avoiding the need for life-long immunosuppressive drugs. Although this study deals only with allotransplants (person to person), the same research team is also applying a tolerance approach to xenotransplants (pig-to-baboon), with encouraging preliminary results. Following is a sampling of the extensive media coverage of the article:

Rejecting defeat: Scientist triumphs after setback in kidney transplant method -- Boston Globe

Some transplant patients OK without years of drug treatment -- Chicago Tribune,1,7130030.story

MGH kidney transplant experiment -- New England Cable News

Organ Transplant Patients Thrive Without Immune-Subduing Drugs -- Bloomberg News

Study: Transplant Patients Stop Rejection Drugs -- All Things Considered/National Public Radio

Kidney and Liver Transplant Rejection Purged by Chimerism -- Med Page Today

New Therapies Could Change Organ Transplants -- HealthDay News

Organ transplants without rejection --

About Xeno

Xeno seeks to develop therapeutic applications of organs and cells derived from genetically engineered pigs as a transplant alternative to human donor sources. Xeno believes that this corporate goal is made possible through the company's position as an exclusive licensee of what Xeno considers to be some of the medical industry's most advanced research, intellectual property and associated technologies, derived from over 15 years of development in the field of xenotransplantation by a major pharmaceutical company and its associated research entities. Xenotransplantation is defined as the transplantation of organs, cells and tissues from one species to another. For information about Xeno or its products and services, please visit


Elliot Lebowitz
President and CEO, Xeno Transplants Corporation

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release that are not historical facts may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by the use of words such as "seek," "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Xeno to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among other things, the need to obtain sufficient capital or a strategic business arrangement to fund Xeno's business goals and objectives, the need to build the infrastructure necessary to support the research of Xeno's xenotransplantation technology, competition, compliance with applicable regulatory requirements and ability to obtain necessary regulatory approvals related to xenotransplantation, the ability to take Xeno's xenotransplantation technology into the clinical trial stage, the likelihood that Xeno's xenotransplantation technology will prove to be successful, and other risk factors discussed in Xeno's periodic filings with the Securities and Exchange Commission.

Contact Information

  • Investor and Media Inquiries:

    Wayne Smith
    Xeno Transplants Corporation
    E-mail: Email Contact
    Suite 2610-1066 West Hastings Street
    Vancouver, B.C. V6E 3X2
    Tel: 604 684-4691
    Fax: 604 684-4601